Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2017
At a glance
- Drugs TAK 003 (Primary)
- Indications Dengue
- Focus Registrational; Therapeutic Use
- Acronyms TIDES
- Sponsors Takeda
- 05 Apr 2017 According to a Takeda media release, initial results are expected in 2018.
- 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2016 According to a media release, first subject has been vaccinated in this trial.